Onconetix Inc. has undertaken a significant capital restructuring initiative. The company closed a $12.9 million private placement featuring Series D preferred stock coupled with warrants. Concurrently, Onconetix settled an $8.8 million debt obligation with Veru Inc., improving its financial position. As part of the same announcement, the firm disclosed the termination of a previously planned merger agreement with Ocuvex Inc. While no operating metrics or product details were provided, the transaction indicates a focus on recapitalizing the business and refocusing strategic priorities. The infusion of new capital combined with the debt settlement is expected to provide additional liquidity for corporate initiatives. Overall, Onconetix appears to be prioritizing financial flexibility and independence following the canceled merger.

Total raised

$13M

Funding rounds

1

Latest round

Series D

Latest activity

Sep 2025